Crystalline Macropa-Ph-NCS Trifluoroacetate for Stable Isolation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing synthesis methods for macropa-(OCH2CH2)-Ph-NCS result in amorphous materials with poor stability, leading to rapid degradation and hygroscopicity, which complicates their use in pharmaceutical applications and limits their scalability for producing stable drug conjugates.
Innovation Solution
The use of trifluoroacetic acid to form a stable salt and crystalline form of macropa-(OCH2CH2)-Ph-NCS, which enhances stability and solubility, allowing for scalable production without aqueous conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If direct purification by chromatography is used to obtain macropa-(OCH2CH2)-Ph-NCS, then the product can be isolated, but it forms an amorphous material with poor stability and rapid degradation
Solution Approach 1:
The patent changes the physical state parameter of the product from amorphous to crystalline by optimizing the chromatography conditions and solvent system. This phase transition from amorphous to crystalline state dramatically improves the stability of macropa-(OCH2CH2)-Ph-NCS, preventing rapid degradation while maintaining isolation purity.
2Productivity
If amorphous macropa-(OCH2CH2)-Ph-NCS is used, then the synthesis can be completed, but the material exhibits hygroscopicity and rapid quality decline upon storage
Solution Approach 1:
The patent applies phase transition from amorphous to crystalline state through optimized chromatography purification. The crystalline form of macropa-(OCH2CH2)-Ph-NCS eliminates hygroscopicity and prevents rapid quality decline during storage, while maintaining synthesis productivity through efficient direct purification.
3Quantity of substance
If aqueous conditions are used for synthesis, then solubility of macropa-(OCH2CH2)-Ph-NH2 is improved, but hydrolysis of the isothiocyanate is accelerated
Solution Approach 1:
The patent uses an organic solvent system (acetonitrile/water mixture with controlled water content) as an intermediary medium that provides sufficient solubility for the starting material macropa-(OCH2CH2)-Ph-NH2 while minimizing hydrolysis of the isothiocyanate group. The optimized solvent composition acts as a mediator between solubility requirements and stability constraints.
4Quantity of substance
If conventional synthesis methods are used, then macropa-(OCH2CH2)-Ph-NCS can be produced, but the process is not suitable for scale-up due to stability issues
Solution Approach 1:
The patent optimizes multiple parameters including solvent composition ratios, chromatography conditions, and purification temperature to produce crystalline macropa-(OCH2CH2)-Ph-NCS. These parameter changes enable scale-up by improving product stability and eliminating hygroscopicity, making the manufacturing process reliable for large-scale production.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The trifluoroacetic acid salt of macropa-(OCH2CH2)-Ph-NCS exhibits increased stability, reduced hygroscopicity, and improved solubility, making it suitable for large-scale production of high-quality drug conjugates.
Implementation Method 1
The use of trifluoroacetic acid to form a stable salt and crystalline form of macropa-(OCH2CH2)-Ph-NCS
Implementation Method 2
direct purification by chromatography, i.e., reversed phase chromatography
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present disclosure relates to the trifluoroacetic salt of a compound of formula (I), a crystalline form thereof, a process for its preparation and its use.